Bayer Class I new drug Finerenone (BAY 94-8862) starting material
Finelidone is the first non-steroidal selective salt corticosteroid receptor antagonist, which can be used in the treatment of diabetic nephropathy, chronic nephropathy and end-stage nephropathy. It can reduce proteinuria and improve glomerular filtration rate.